Cognitive · Brain-derived peptide hydrolysate · Compounded 503A
Cerebroprotein hydrolysate: neuropeptide nootropic.
Cerebroprotein hydrolysate — most commonly known by the brand name Cerebrolysin — is a porcine brain-derived peptide preparation containing free amino acids and low-molecular-weight neuropeptides. In countries where it is approved, it is used for cognitive support after stroke, traumatic brain injury, and in dementia. It is one of the most extensively studied 'pleiotropic' nootropic peptide preparations.
What Cerebroprotein Hydrolysate is
Cerebroprotein hydrolysate is a standardized preparation of low-molecular-weight peptides (<10 kDa) and free amino acids derived from purified porcine brain protein. The original branded product (Cerebrolysin) was developed in the 1950s and has been used clinically in Europe, Asia, and Russia for decades.
Unlike a single-molecule drug, it is a complex preparation — the therapeutic activity comes from the combined action of many peptide fragments that mimic endogenous neurotrophic factor activity (BDNF, NGF, CNTF, GDNF).
It is approved in over 50 countries for indications including ischemic stroke recovery, traumatic brain injury, vascular dementia, and Alzheimer's disease. It is not FDA-approved in the United States; compounded forms are dispensed through 503A pharmacies under physician prescription.
How it works
The active peptide fractions act on neurons through several overlapping mechanisms: mimicking neurotrophic factor activity (binding TrkA and TrkB receptors), reducing excitotoxic glutamate signaling, modulating microglial inflammatory response, and stimulating neurogenesis in the hippocampus.
It crosses the blood-brain barrier and is taken up by neurons, where the peptide fragments support neuronal survival, axonal sprouting, and synaptic plasticity.
The net effect — characterized over decades of European and Asian clinical use — is a 'pleiotropic' (multi-pathway) neuroprotective and neurotrophic signal, rather than a single targeted drug action.
What patients use it for
Post-stroke recovery
Multiple large RCTs (CARS, CASTA) show improved motor and cognitive recovery when added to standard post-stroke care.
Traumatic brain injury
Cochrane reviews and meta-analyses suggest improved outcomes in moderate-to-severe TBI when given in the acute and subacute phases.
Vascular dementia and Alzheimer’s
Evidence base supports modest cognitive improvement in vascular dementia and mild-to-moderate Alzheimer’s.
Cognitive support (off-label)
Off-label use for general cognitive support, post-concussion, and age-related cognitive decline is common in compounded practice — supported by mechanism but not by U.S. FDA approval.
Evidence summary
Heiss WD et al. (Stroke, 2012) CARS RCT — improved motor recovery with Cerebrolysin in post-stroke rehabilitation.
Muresanu DF et al. (CNS Neurosci Ther, 2014, 2016) demonstrated cognitive recovery benefits in TBI populations.
Cochrane reviews of Cerebrolysin for acute ischemic stroke and vascular dementia have characterized the evidence as positive but heterogeneous.
Decades of post-marketing safety data from European and Asian clinical practice provide a strong safety profile.
Dosing and clinical context
General clinical context only. Kindr Health physicians determine the appropriate dose and protocol for each patient based on history and labs. This is not a prescription or dosing recommendation.
Intramuscular or slow IV injection, typically in 5–30 mL dose ranges depending on indication.
Course-based protocols (10–20 day cycles, repeated 2–4 times per year) are standard.
Compounded by licensed 503A pharmacies in the U.S.; branded Cerebrolysin is imported under physician discretion in some practices.
Safety and contraindications
Generally very well tolerated. Most-reported issues: transient injection-site reactions, mild flushing, occasional dizziness.
Contraindications: known protein hypersensitivity, severe renal impairment, status epilepticus, pregnancy/lactation (precautionary), pediatric use (off-label).
Rare allergic reactions are possible given the porcine-origin protein composition.
Not FDA-approved in the U.S.; approved and widely used in over 50 other countries for neurological indications.
Who it's typically considered for
- Adults in post-stroke or post-TBI recovery (under neurologist or rehabilitation physician supervision)
- Patients with vascular dementia or mild-to-moderate Alzheimer’s pursuing adjunctive cognitive support
- Patients with post-concussion symptoms persisting beyond standard recovery windows
- Adults with age-related cognitive decline seeking pleiotropic neurotrophic support
Frequently asked questions
Is cerebroprotein the same as Cerebrolysin?
Functionally yes — cerebroprotein hydrolysate is the generic / compounded preparation; Cerebrolysin is the original branded product (EVER Pharma). Both are porcine brain-derived peptide hydrolysates.
Cerebroprotein vs Semax or Selank?
Different mechanisms. Semax and Selank are short, single-sequence peptides (ACTH and tuftsin-derived respectively). Cerebroprotein is a complex hydrolysate with broad neurotrophic activity.
Is cerebroprotein FDA-approved?
No. It is approved in over 50 countries for neurological indications. In the U.S. it is compounded by licensed 503A pharmacies under physician prescription for off-label use.
How fast does it work?
Stroke and TBI recovery effects build over a course of treatment (weeks). Cognitive support effects in dementia are typically evaluated at 12 weeks.
Is it safe long-term?
Decades of European and Asian post-marketing data support a strong long-term safety profile in approved indications.
Can it cure Alzheimer’s?
No. Evidence supports modest cognitive benefit as an adjunct in mild-to-moderate disease, not disease modification or cure.
Sources
- Heiss WD et al. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke (2012). — pubmed.ncbi.nlm.nih.gov/22198983
- Muresanu DF et al. Cerebrolysin and recovery after stroke (CARS): a randomized, placebo-controlled, double-blind, multicentre trial. Stroke (2016). — pubmed.ncbi.nlm.nih.gov/26797664
- Plosker GL, Gauthier S. Cerebrolysin: a review of its use in dementia. Drugs Aging (2009). — pubmed.ncbi.nlm.nih.gov/19888785
Considering Cerebroprotein Hydrolysate?
A Kindr Health physician reviews every longevity intake — peptides are prescribed only when medically indicated based on your history and labs. There is no charge for the initial review.
Start your longevity intake →Related peptides
Medically reviewed by Dr. Ana Lisa Carr, MD, MBA
Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer
NPI 1689841744 · Last reviewed: May 10, 2026
Last reviewed May 10, 2026. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products. Prescriptions require a clinical evaluation; a Kindr Health physician determines eligibility. Not for use in pregnancy. This page provides educational information and is not medical advice.